Related Experiment Video
Updated: Aug 18, 2026

Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model
Published on: April 13, 2015
Changes in T-cell subsets and their clinical significance in cancer patients
Abstract:
The proportion of T cells that have receptors for IgG-Fc (Fc R+ T cells), the functioning of T cell helpers in immunoglobulin production and the blastogenic response of lymphocytes to PHA and Con A were measured in cancer patients. Increases in the percentage of IgG-Fc R+ T cells were observed in most patients; these were greater in patients with advanced tumours and fell within the normal range after complete surgical removal of the tumour. The functioning of T cell helpers in immunoglobulin production and response of lymphocytes to PHA were poor in those patients in whom IgG-Fc R+ T cell percentages were increased. The lymphocytes of such patients responded well to Con A. These changes in T-cell subsets appear to be related to the presence and progress of tumours.
Related Concept Videos
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Tumor Immunotherapy

